Education
About Us
Working with TipRanks
Follow Us
Immuneering Corp. Class A (IMRX)
:IMRX
Top Page
Immuneering
(NASDAQ:IMRX)
37Underperform
Positive Factors
Clinical Collaborations
Partnering with a global pharmaceutical company like Regeneron provides external validation of Immuneering's technology.
Efficacy Data
Initial Phase 2a efficacy data from IMM-1-104 in combination with chemotherapy shows a promising overall response rate of 40% and a disease control rate of 80%.
Negative Factors
Stock Performance
Despite the positive data, the stock has surprisingly declined since the announcement.
Immuneering (IMRX) vs. S&P 500 (SPY)
Market Cap
$46.58M
Dividend YieldN/A
Average Volume (3M)261.99K
Price to Earnings (P/E)―
Beta (1Y)2.21
Revenue Growth-100.00%
EPS Growth-5.05%
CountryUS
Employees68
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.97
Shares Outstanding31,050,447
10 Day Avg. Volume204,857
30 Day Avg. Volume261,988
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2425.82
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$10.00Price Target Upside566.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Immuneering Business Overview & Revenue Model
Company DescriptionImmuneering Corpbiopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to leading pharmaceutical and biotechnology companies.
How the Company Makes MoneyImmuneering makes money primarily through the development and commercialization of its proprietary drug candidates. The company generates revenue through collaborations and partnerships with other pharmaceutical companies, which may include milestone payments and royalties based on the successful development and commercialization of joint therapies. Additionally, Immuneering may receive funding through grants and research contracts that support its ongoing research efforts. As a biotechnology company, its primary focus is on advancing its pipeline towards clinical trials and eventual market approval, which would enable it to gain revenue from sales of its therapeutic products.
Immuneering Financial Statement Overview
Summary
Immuneering faces severe financial challenges across all financial statements, with declining revenue, widening losses, and cash flow difficulties. The income statement shows significant operational difficulties with negative revenue growth and deteriorating profit margins. The balance sheet indicates low leverage but highlights risks due to persistent negative equity. Cash flow analysis reveals cash burn issues and insufficient cash generation.Income Statement
Immuneering's income statement reveals significant challenges, with negative revenue and deteriorating profit margins. The TTM shows a worsening trend with a gross profit margin of -100.58% and a net profit margin of -61.51%. Revenue growth is negative, indicating a decline in financial performance. These factors suggest substantial operational difficulties.15
Very Negative
Balance Sheet
The balance sheet highlights a concerning financial position with a debt-to-equity ratio of 0.07, indicating low leverage but potentially due to declining equity. The equity ratio is 84.21%, showing reliance on equity financing. However, the persistent negative equity in past years is a significant risk factor.35
Negative
Cash Flow
Cash flow analysis shows negative operating cash flow and free cash flow, reflecting cash burn issues. The TTM free cash flow growth is negative, and the operating cash flow to net income ratio indicates insufficient cash generation relative to losses. These factors demonstrate cash flow instability.20
Very Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| -94.42M | 0.00 | 316.95K | 2.08M | 2.31M | 1.92M | Gross Profit |
| -94.97M | -764.14K | 158.83K | 926.89K | 1.03M | 696.74K | EBIT |
| -61.82M | -58.41M | -51.74M | -33.89M | -17.08M | -6.29M | EBITDA |
| -60.12M | -58.06M | -51.47M | -33.68M | -17.00M | -7.34M | Net Income Common Stockholders |
| -58.07M | -53.47M | -49.28M | -33.54M | -17.04M | -8.06M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 13.78M | 85.67M | 105.52M | 149.20M | 37.09M | 13.78M | Total Assets |
| 0.00 | 102.58M | 122.37M | 166.70M | 38.42M | 14.10M | Total Debt |
| 0.00 | 4.46M | 4.84M | 5.36M | 621.09K | 16.61M | Net Debt |
| 13.78M | -54.94M | -67.80M | -69.52M | -36.47M | 2.83M | Total Liabilities |
| 0.00 | 12.01M | 12.52M | 10.72M | 60.90M | 20.63M | Stockholders Equity |
| 10.08M | 90.58M | 109.85M | 155.98M | -22.48M | -6.53M |
| Cash Flow | Free Cash Flow | ||||
| -52.51M | -49.31M | -44.84M | -30.91M | -14.67M | -4.46M | Operating Cash Flow |
| -52.26M | -48.97M | -44.10M | -30.85M | -14.62M | -4.44M | Investing Cash Flow |
| 24.08M | 7.30M | 41.83M | -75.62M | -53.41K | -20.53K | Financing Cash Flow |
| 5.35M | 28.44M | 19.00K | 144.26M | 37.98M | 17.17M |
Immuneering Technical Analysis
Negative
1.50
Price Trends
1.88
Negative
1.95
Negative
1.75
Negative
Market Momentum
-0.11
Positive
35.78
Neutral
29.53
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMRX, the sentiment is Negative. The current price of 1.5 is below the 20-day moving average (MA) of 1.65, below the 50-day MA of 1.88, and below the 200-day MA of 1.75, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 35.78 is Neutral, neither overbought nor oversold. The STOCH value of 29.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IMRX.
Immuneering Risk Analysis
Immuneering disclosed 90 risk factors in its most recent earnings report. Immuneering reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Immuneering Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $10.96B | 22.09 | 23.13% | ― | 18.49% | 176.71% | |
64 Neutral | $125.40B | ― | -3.15% | ― | 11.64% | -114.72% | |
60 Neutral | $13.17B | 251.00 | 0.76% | ― | 14.76% | -88.32% | |
52 Neutral | $5.61B | ― | -31.26% | ― | 104.04% | 87.80% | |
49 Neutral | $6.90B | 0.02 | -54.05% | 2.46% | 24.91% | -3.14% | |
49 Neutral | $30.91B | ― | -414.62% | ― | 22.97% | 38.54% | |
37 Underperform | $46.58M | ― | -71.81% | ― | -100.00% | -5.05% |
* Healthcare Sector Average
Performance Comparison
IMRX
Immuneering
1.52
-4.36
-74.15%
ALNY
Alnylam Pharma
242.43
94.01
63.34%
EXEL
Exelixis
37.20
14.13
61.25%
INCY
Incyte
67.73
8.81
14.95%
VRTX
Vertex Pharmaceuticals
495.42
82.22
19.90%
BPMC
Blueprint Medicines
90.50
-0.10
-0.11%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.